Overview

Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens

Status:
Completed
Trial end date:
2021-11-22
Target enrollment:
Participant gender:
Summary
This study is to compare the pharmacokinetics (how the body absorbs, breaks down and eliminates drug from your body) of nalmefene when given as a single dose intranasally (IN;into the nose), as a single dose in each nostril and as two doses in one nostrils; and to evaluate the safety and tolerability of nalmefene IN.
Phase:
Phase 1
Details
Lead Sponsor:
Opiant Pharmaceuticals Inc
Treatments:
Nalmefene